| 2026-03-26 |
详情>>
内部人交易：
Banjak Marc共交易2笔
|
| 2026-02-27 |
详情>>
股本变动：
变动后总股本3454.36万股
|
| 2026-02-10 |
详情>>
业绩披露：
2026年中报每股收益-0.19美元,归母净利润-1471.3万美元,同比去年增长-76.14%
|
| 2025-12-08 |
复牌提示：
2025-12-08 09:38:52 停牌，复牌日期 2025-12-08 09:43:52
|
| 2025-11-17 |
详情>>
业绩披露：
2026年一季报每股收益-0.11美元,归母净利润-572万美元,同比去年增长-43.39%
|
| 2025-10-06 |
股东大会：
将于2025-11-20召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for Class II director named in the accompanying proxy statement to our Board of Directors, each to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of Grassi & Co., CPAs, P.C. as our independent registered public accounting firm for our fiscal year ending on June 30, 2026;
3.To approve, on an advisory, non-binding basis, the compensation of our named executive officers (Say-on-Pay);
4.To approve, on an advisory, non-binding basis, the frequency of future executive compensation advisory votes.
|
| 2025-09-05 |
详情>>
业绩披露：
2025年年报每股收益-1.75美元,归母净利润-1837.7万美元,同比去年增长26.22%
|
| 2025-05-02 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.44美元,归母净利润-1321.4万美元,同比去年增长22.86%
|
| 2025-02-10 |
详情>>
业绩披露：
2025年中报每股收益-0.94美元,归母净利润-835.3万美元,同比去年增长40.15%
|
| 2024-11-12 |
详情>>
业绩披露：
2025年一季报每股收益-0.46美元,归母净利润-398.9万美元,同比去年增长30.58%
|
| 2024-10-10 |
股东大会：
将于2024-11-21召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees for Class I director named in the accompanying proxy statement to our Board of Directors, each to serve a three-year term expiring at the 2027 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of Grassi & Co., CPAs, P.C. as our independent registered public accounting firm for our fiscal year ending on June 30, 2025;
3.To approve, on an advisory, non-binding basis, the compensation of our named executive officers (Say-on-Pay).
|
| 2024-09-24 |
详情>>
业绩披露：
2024年年报每股收益-6.5美元,归母净利润-2490.7万美元,同比去年增长61.69%
|
| 2024-05-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-7.62美元,归母净利润-1712.9万美元,同比去年增长70.96%
|
| 2024-02-09 |
详情>>
业绩披露：
2024年中报每股收益-9.15美元,归母净利润-1395.7万美元,同比去年增长72.99%
|
| 2023-11-29 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2023-11-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.24美元,归母净利润-574.6万美元,同比去年增长68.31%
|
| 2023-10-26 |
股东大会：
将于2023-11-27召开股东大会
会议内容 ▼▲
- 1.To elect the two (2) nominees for Class III director named in the accompanying proxy statement to our Board of Directors, each to serve a three-year term expiring at the 2026 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for our fiscal year ending on June 30, 2024;
3.To approve, on an advisory, non-binding basis, the compensation of our named executive officers (Say-on-Pay);
4.To approve an amendment to the Company’s Certificate of Incorporation, in substantially the form attached to the accompanying proxy statement as Appendix A, at the discretion of the Board of Directors of the Company, to effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.001 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range (the “Reverse Stock Split Ratio”) to be determined at the discretion of the Board and included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment;
5.To approve the adoption of the iBio, Inc. 2023 Omnibus Equity Incentive Plan (the “2023 Plan”), in the form attached to the accompanying proxy statement as Appendix B;
6.To approve an adjournment of the 2023 Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of Proposal 4 and/or Proposal 5;
7.To transact such other business as may properly come before the 2023 Annual Meeting or any adjournments or postponements of the 2023 Annual Meeting.
|
| 2022-10-26 |
股东大会：
将于2022-12-08召开股东大会
会议内容 ▼▲
- 1.To elect the two (2) nominees for Class II directors named herein to our Board of Directors, each to serve a three-year term expiring at the 2025 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for our fiscal year ending on June 30, 2023;
3.To approve, on an advisory, non-binding basis, the compensation of our named executive officers (Say-on-Pay);
4.To transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2022-10-10 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2022-06-14 |
股东大会：
将于2022-06-30召开股东大会
会议内容 ▼▲
- 1.An amendment to our certificate of incorporation, as amended, to effect a reverse stock split (the “reverse stock split”) of our issued and outstanding shares of common stock, $0.001 par value per share (the “common stock”), at the ratio of one (1) share of common stock for every twenty five (25) shares of common stock (the “reverse stock split ratio”), such amendment to be effected after stockholder approval thereof only in the event the board of directors still deems it advisable (the “reverse stock split proposal”);
2.An amendment to our certificate of incorporation, as amended, to decrease, immediately following and conditioned upon the effectiveness of the reverse stock split, the number of authorized shares of common stock (the “authorized share decrease”) from 275,000,000 to 22,000,000 (the “authorized share decrease proposal”);
3.A proposal to adjourn the special meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of either the reserve stock split proposal and/or the authorized share decrease proposal.
|
| 2022-05-12 |
财报披露：
美东时间 2022-05-12 盘后发布财报
|
| 2021-10-26 |
股东大会：
将于2021-12-09召开股东大会
会议内容 ▼▲
- 1.to elect the three (3) nominees named herein as Class I directors of our Board of Directors, each to serve a three-year term expiring at the 2024 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified;
2.to ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for our fiscal year ending on June 30, 2022;
3.to approve, on an advisory, non-binding basis, the compensation of our named executive officers (Say-on-Pay);
4.to approve an amendment to our Certificate of Incorporation, as amended, to effect a reverse stock split (the “Reverse Stock Split”) of our issued and outstanding shares of Common Stock, $0.001 par value per share, at the ratio of one (1) share of Common Stock for every ten (10) shares of Common Stock (the “Reverse Stock Split Ratio”), such amendment to be effected after stockholder approval thereof only in the event the Board of Directors still deems it advisable;
5.to approve an amendment to our Certificate of Incorporation, as amended, to decrease, concurrent with and conditioned upon the effectiveness of the Reverse Stock Split, the number of authorized shares of Common Stock from 275,000,000 to 55,000,000 (the “Authorized Share Decrease Proposal”);
6.to approve an adjournment of the 2021 Annual Meeting, if the Board of Directors determines it to be necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of either proposals (4) or (5) above;
7.to transact any other business properly brought before the 2021 Annual Meeting or any postponement or adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-11-06 |
股东大会：
将于2020-12-09召开股东大会
会议内容 ▼▲
- 1.to elect the three (3) nominees named herein as Class III directors of our Board of Directors, each to serve a three-year term expiring at the 2023 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified;
2.to ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for our fiscal year ending on June 30, 2021;
3.To approve an advisory vote on Executive Compensation (“say-on-pay”);
4.to approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 275,000,000 to 425,000,000, such amendment to be effected after stockholder approval thereof only in the event the Board of Directors still deems it advisable;
5.to approve the adoption of the iBio, Inc. 2020 Omnibus Equity Incentive Plan (the “2020 Plan”);
6.to approve an adjournment of the 2020 Annual Meeting, if the Board of Directors determines it to be necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of either proposals (4) or (5) above;
7.to transact any other business properly brought before the 2020 Annual Meeting or any postponement or adjournment thereof.
|
| 2020-01-23 |
股东大会：
将于2020-02-10召开股东大会
会议内容 ▼▲
- 1.To elect two directors each to serve as Class II directors for a three-year term expiring at the 2022 annual meeting of stockholders or until successors have been duly elected and qualified;
2.To ratify the selection of CohnReznick LLP as our independent registered public accounting firm for the current fiscal year ending June 30, 2020;
3.To approve an advisory vote on executive compensation;
4.To hold an advisory vote on the frequency of future executive compensation advisory votes;
5.To approve an amendment to our Certificate of Incorporation, as amended, to effect a reverse stock split of our Common Stock, $0.001 par value per share, at a ratio not less than one-for-five (1:5) and not greater than one-for-twenty-five (1:25), with the exact ratio to be publicly announced and set within that range at the discretion of our Board of Directors before filing of the amendment effecting the proposed reverse stock split without further approval or authorization of our stockholders;
6.To approve an amendment to our 2018 Omnibus Equity Incentive Plan to increase the number of shares of our common stock authorized for issuance thereunder from 3.5 million shares to 6.5 million shares and to incorporate changes to include restricted stock units and performance-based awards as grant types issuable under the 2018 Omnibus Equity Incentive Plan;
7.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2018-11-19 |
股东大会：
将于2018-12-18召开股东大会
会议内容 ▼▲
- 1.To elect three directors each to serve as Class I directors for a three-year term expiring at the 2021 annual meeting of stockholders or until successors have been duly elected and qualified;
2.To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2019;
3.To approve an advisory vote on executive compensation (“say-on-pay”);
4.To consider and approve the Company’s 2018 Omnibus Equity Incentive Plan;
5.To consider and approve an amendment to the Company’s 2008 Omnibus Equity Incentive Plan to permit a one-time option exchange;
6.To transact any other business properly brought before the annual meeting.
|
| 2018-05-31 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2018-04-03 |
股东大会：
将于2018-04-23召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Certificate of Incorporation, as amended, to effect a reverse stock split of our Common Stock, $0.001 par value per share, at a ratio not less than one-for-two (1:2) and not greater than one-for-ten (1:10), with the exact ratio to be publicly announced and set within that range at the discretion of our Board of Directors before filing of the amendment effecting the proposed reverse stock split without further approval or authorization of our stockholders;
2.To consider and vote upon a proposal to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposal to effect a reverse stock split (Proposal 1);
3.To transact any other business properly brought before the meeting.
|
| 2017-11-27 |
股东大会：
将于2017-12-19召开股东大会
会议内容 ▼▲
- 1.To elect two directors each to serve as Class III directors for a three year term expiring at the 2020 annual meeting of stockholders or until successors have been duly elected and qualified;
2.To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2018;
3.To approve an advisory vote on executive compensation (“say-on-pay”);
4.To approve an amendment to our certificate of incorporation, as amended, increasing the number of authorized shares of our common stock from 175 million shares to 275 million shares;
5.To approve an amendment to our 2008 Omnibus Equity Incentive Plan, as amended, to increase the number of shares of our common stock authorized for issuance thereunder from 15 million shares to 25 million shares;
6.To transact any other business properly brought before the annual meeting.
|
| 2017-04-06 |
股东大会：
将于2017-05-04召开股东大会
会议内容 ▼▲
- 1.To elect two directors each to serve as Class II directors for a three year term expiring at the 2019 annual meeting of stockholders or until successors have been duly elected and qualified;
2.To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2017;
3.To approve an advisory vote on executive compensation (“say on pay”);
4.To transact any other business properly brought before the annual meeting.
|
| 2016-03-25 |
股东大会：
将于2016-04-07召开股东大会
会议内容 ▼▲
- 1.To elect three directors each to serve as Class I directors for a three year term expiring at the 2018 annual meeting of stockholders or until successors have been duly elected and qualified;
2.To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2016;
3.To approve an advisory vote on executive compensation (“say on pay”);
4.To approve, in accordance with NYSE MKT rules, the issuance to Eastern Capital Limited of 6,500,000 shares of our common stock at a purchase price of $0.622 per share;
5.To transact any other business properly brought before the annual meeting.
|